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 Pre- (and peri-ischemia) conditioning is a
potentially powerful protector against
ischemia–reperfusion injury, and activa-
tion of ALDH2 may be a critical step.
 The authors demonstrate second-window
pre-conditioning (i.e., with the stimulus
24 h before ischemia) with-low dose so-
dium nitrite in the vascular endothelium
of healthy human volunteers.
 They go on to show that nitrite,
administered during ischemia, also
affords protection to vascular
endothelium in participants with the
common worldwide variant ALDH2*2
enzyme, but not in those with wild-type
ALDH2, using this particular protocol.
 This surprising result shows the
challenges of translation in this particular
area and the critical importance of dose,
location, and timing of the conditioning
stimulus.rtment of Medicine, University of
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sity of Birmingham, Birmingham,
uthampton, Southampton, United
is study was funded by a program
nships relevant to the contents of
November 4, 2016.
ABBR EV I A T I ON S
AND ACRONYMS
Ach = acetylcholine
ALDH2 = mitochondrial
aldehyde dehydrogenase
FBF = forearm blood ﬂow
FBF-R = forearm blood
ﬂow ratio
GTN = glyceryl trinitrate
IR = ischemia–reperfusion
RIPC = remote ischemic pre-
conditioning
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14SUMMARYPre-conditioning is an exciting physiological phenomenon that, despite great efforts, has so far resisted
translation to mainstream clinical medicine. Many potential triggers (e.g., ischemia of the organ in question or a
remote organ, many different drugs) have been investigated, but recent work has implicated activation of
mitochondrial aldehyde dehydrogenase (ALDH2) as central to the process. A genetic polymorphism, known as
ALDH2*2, is common worldwide (present in up to 40% of Han Chinese people) and produces a functionally
different enzyme. The authors used a variety of protocols in the human ischemic forearm model, in participants
with both enzyme types, to assess cytoprotection with low-dose sodium nitrite and attempt to further
elucidate the role of ALDH2. (J Am Coll Cardiol Basic Trans Science 2017;2:13–21) © 2017 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).T here has been great interest in possiblebeneﬁcial effects of inorganic nitrite (NO2)in recent years (1–3). Nitrite may have a
role in hypoxic vasodilation (4) and has been shown
to protect renal tissue (5,6), liver (7), and myocar-
dium (8,9) from ischemia–reperfusion (IR) injury in
animal models. Nitrate (NO3), administered orally
in beetroot juice, protected endothelium from IR
injury in healthy human volunteers (9), an effect
attributed to a 2-fold increase in plasma nitrite.
More recent work by Ingram et al. (10) in a human
forearm model of reperfusion injury demonstrated
a protective effect of a 20-min intravenous infusion
of sodium nitrite (1.5 mmol/min) administered before
the onset of ischemia (pre-conditioning), but admin-
istration of the same nitrite infusion during forearm
ischemia (post-conditioning) resulted in no reduc-
tion in the degree of endothelial dysfunction
compared with placebo. This lack of protection
from nitrite administered during an ischemic insult
contradicts the protective effects observed by Gon-
zalez et al. (8) in a canine model of myocardial
infarction. The NIAMI (Nitrite in Acute Myocardial
Infarction) study randomized 280 patients with ST-
segment elevation myocardial infarction to receive
70 mmol sodium nitrite or placebo intravenously in
the 5 min immediately before reperfusion (11). This
post-conditioning protocol demonstrated no differ-
ence in infarct size at either 8 days or 6 months as
determined by cardiac magnetic resonance imaging.
Mitochondrial aldehyde dehydrogenase (ALDH2) is
a member of the 19-strong human aldehyde dehy-
drogenase family of NAD(P)þ-dependent enzymes
(12). A common polymorphism in exon 12 (Glu487Lys,
or Glu504Lys in the unspliced protein), known as the
ALDH2*2 allele, is present in up to 50% of individuals
of East Asian descent (13). Heterozygosity at this
allele results in a near inactive enzyme and produces
the “Asian Flushing” phenotype, a phenomenonlinked to the accumulation of acetaldehyde following
alcohol ingestion; mutation of a single subunit de-
stabilizes the cofactor binding site and dimer inter-
face such that heterozygotes are functionally similar
to homozygotes with the variant allele (14). In-
dividuals possessing 1 or 2 copies of the ALDH2*2
allele may be at greater risk of coronary artery disease
(15) and myocardial infarction (16). ALDH2 activation
by phosphorylation has been postulated to be central
to protection conferred against myocardial ischemia
reperfusion injury (17). Pre-conditioning was induced
by activation of PKCε (which phosphorylates ALDH2)
and subsequently by a direct activator of ALDH2,
alda-1. In a later study, the volatile anesthetic iso-
ﬂurane induced cardioprotection in a rat model (18).
Protection was associated with activation of ALDH2
and was abolished by an inhibitor of PKCε. On the
basis of these data, combined with the observation
that ALDH2 also exhibits intrinsic nitrite reductase
activity (19), we hypothesized that an interaction
between ALDH2 and nitrite might contribute to IR
protection in humans.
We hypothesized that nitrite would be protective
in the human forearm, either when administered 24 h
before ischemia reperfusion (“second-window pre-
conditioning”) or when administered during ischemia
(with the primary effect in the “post-conditioning”
window), and that its protective effects would be
modiﬁed by variations in ALDH2 activity. We used a
combination of genetic and pharmacological tools in
an established model of IR injury in the human fore-
arm (20), to investigate protection by nitrite and the
role of ALDH2.
METHODS
This study was approved by the local research ethics
committee. All participants gave written informed
consent. All studies were performed in a dedicated
TABLE 1 Baseline Characteristics of Participants in Each Group
Delayed ALDH2*1/*2 ALDH2*1/*1 Disulﬁram
Height (m) 1.71  0.05 1.72  0.03 1.68  0.03 1.83  0.03
Weight (kg) 64.2  6.3 61.6  4.4 63.7  2.6 77.5  4.5
BMI (kg/m2) 21.5  0.8 20.6  0.8 22.6  0.6 23.1  1.0
Forearm (cm) 23.6  0.9 23.0  0.8 24.2  0.4 25.6  0.9
Age (yrs) 25.0  1.0 23.0  0.7 23.0  0.7 24.0  1.3
Individuals tested 7 11 11 6
Male/female 4/3 6/5 7/4 6/0
HR placebo (beats/min) — 75  3 61  1 —
HR nitrite (beats/min) 66  3 73  3 64  3 62  5
MABP placebo (mm Hg) — 84  4 84  5 —
MABP nitrite (mm Hg) 87  4 85  3 81  3 89  3
Values are mean  SD or n.
ALDH2 ¼ mitochondrial aldehyde dehydrogenase; BMI ¼ body mass index; HR ¼ heart rate; MABP ¼ mean
arterial blood pressure.
FIGURE 1 The Basic Study Design and Plan of Each Study
(A) Basic design followed for each individual study, ACh FBF: measurement of
endothelium-dependent forearm blood ﬂow increase; GTN FBF: measurement of
endothelium-independent forearm blood ﬂow increase. (B) Summarizing the 3 protocols;
there was a washout period of >1 week between any given studies in the same
participant. Ach ¼ acetylcholine; FBF ¼ forearm blood ﬂow; GTN ¼ glyceryl trinitrate.
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15vascular laboratory, maintained at 22C to 24C in
quiet conditions. All participants were nonsmokers,
and none was on medications of any kind. The
baseline characteristics are given in Table 1. All
participants avoided nitrite/nitrate-rich foods or
alcohol for 24 h before the study, and abstained from
caffeine on the day of the study. There was a
washout period of >1 week between runs in the
same patient.
FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY.
Participants were seated upright on the bed with
both arms exposed, fully extended, and supported at
heart level. Mercury-in-silastic strain gauges of an
appropriate size were placed around the widest
portion of each forearm. The nondominant brachial
artery was cannulated using a 27-gauge needle
(Cooper’s Needleworks, Birmingham, United
Kingdom) attached to an epidural catheter and
sealed with dental wax under aseptic conditions,
with lignocaine anesthesia at the participant’s
discretion. Saline (0.9% NaCl, with or without
agonists/drugs) was infused at 0.5 ml/min at all
times to maintain needle patency. Venous access
was gained with a 20-gauge cannula in the ante-
cubital fossa of the control arm. Blood pressure and
heart rate were continuously monitored. Forearm
blood ﬂow (FBF) was measured simultaneously in
both arms using venous occlusion plethysmography
to determine the FBF-ratio (FBF-R). Wrist cuffs were
inﬂated to 200 mm Hg in order to exclude the hand
circulation during measurements and were deﬂated
between each set of measurements. FBF-R was
measured at rest and again after 3-min intra-arterial
infusion of acetylcholine (ACh) into the study arm at
each of 3 ascending doses (25, 50, and 100 nmol/min).
Endothelial function was assessed using the change
in FBF-R from baseline. Endothelium-independent
vasorelaxant effects were determined only once at
the end of each study in the main group by intra-
arterial infusion of glyceryl trinitrate (GTN) (at 3
ascending doses: 4, 8, and 16 nmol/min), in order to
prevent potential confounding effects of GTN before
ischemia (17).
IR PROTOCOL. Following 15 min of stabilization
following arterial cannulation, baseline endothelial
function was measured. A 5-min washout was
allowed to elapse from the end of the last infusion
before forearm ischemia was induced by inﬂating the
upper arm cuff on the study arm to >200 mm Hg for a
period of 20 min. Endothelial function was then
remeasured after 15 min of reperfusion, to assess the
level of endothelial IR injury. This protocol has
been demonstrated to cause transient endothelialdysfunction that is manifest after 15 min of reperfu-
sion and lasting up to 60 min (20). The study design is
summarized in Figure 1A.
NITRITE INFUSION. Sodium nitrite (Martindale
Pharma, Wooburn Green, United Kingdom) or saline
placebo was infused intravenously into the control
arm at a dose of 1 mg/kg/min for 10 min. The dosage of
FIGURE 2 Intravenous Sodium Nitrite Induced Second-Window Pre-Conditioning in
ALDH2*1/*1 Individuals
Increase in FBF in response to ACh in individuals before and after 20 min of limb ischemia;
(A) 20 min of forearm ischemia produced signiﬁcant endothelial dysfunction (saline
placebo 24 h pre-ischemia, pre- vs. post-ischemia FBF-R; p ¼ 0.047 across all ACh doses,
n ¼ 5). (B) Intravenous sodium nitrite (1 mg/kg/min) administered 24 h before ischemia
prevented endothelial dysfunction (pre- vs. post-ischemia FBF-R; p ¼ 0.78 across all
ACh doses, n ¼ 7); *p < 0.05. Solid circles ¼ pre-ischemia FBF-R; open circles ¼ post-
ischemia FBF-R. FBF-R ¼ forearm blood ﬂow ratio; other abbreviations as in Figure 1.
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16nitrite was chosen because it does not cause signiﬁ-
cant vasodilation or venodilation (4).
BLOOD SAMPLING. Venous blood samples were
taken before ischemia and then after 1 min of reper-
fusion. Samples were placed in tubes spiked with
EDTA (10 mmol/l) and NEM (2 mmol/l), transferred on
ice to a chilled (4C) centrifuge, and then spun at
4,000 rpm for 15 min. Plasma samples were then snap
frozen in liquid nitrogen and stored at 80C. Plasma
nitrate/nitrite (NOx) and nitrosylated species (RXNO)
levels were measured using gas-phase chem-
iluminescence (21).
DETERMINATION OF ALDH2 GENOTYPE. Partici-
pants were not asked at any stage and were discour-
aged from discussing whether they possessed any
features of the “ﬂushing” phenotype in order to pre-
serve blinding. Genetic analysis for ALDH2 genotype
was performed for all participants after the comple-
tion of studies, in order to maintain blinding. DNA
was extracted from venous blood samples (QIAamp,
Qiagen, Hilden, Germany) and analyzed using com-
mercial probes and primers (Taqman System, Applied
Biosciences, Thermo Fisher Scientiﬁc, Waltham,
Massachusetts). One participant was found to be ho-
mozygous at the *2 allele. This dataset was excluded
from the analysis.ALDH2-DEPENDENT INACTIVATION BY NITRITE.
Expression and puriﬁcation of ALDH2 was performed
as previously described (22). Dehydrogenase activity
was measured by monitoring the formation of NADH
as an increase in light absorbance at 340 nm in
50 mmol/l sodium pyrophosphate buffer (pH 7.5)
containing 0.4 mmol/l acetaldehyde, 10 mmol/l
MgCl2, and 5 mmol/l NAD. After 2 min of equilibra-
tion, the reactions were started by the addition of
ALDH2*1 or ALDH2*2 (19 and 111 mg/ml ﬁnal concen-
trations, respectively) and monitored for w3 min to
obtain initial reaction rates. Activities were subse-
quently measured after the addition of 10 mmol/l
NaNO2 and 1 mmol/l dithiothreitol.
TREATMENT PROTOCOLS. Treatment protocols are
summarized in Figure 1B.
PROTOCOL 1: SECOND-WINDOW PRE-CONDITIONING BY
NITRITE. Twelve Caucasians were recruited to the
delayed (second-window) pre-conditioning group. A
10-min infusion of nitrite (or saline placebo) was
administered intravenously 24 h before the onset of
ischemia.
PROTOCOL 2: EFFECT OF GENETIC POLYMORPHISM
ON FIRST-WINDOW NITRITE POST-CONDITIONING.
Twenty-two healthy volunteers of East Asian origin
were recruited to a randomized double-blind placebo-
controlled crossover study. Nitrite or placebo was
administered for 10 min during the second half of the
20-min ischemia period.
PROTOCOL 3: EFFECT OF PHARMACOLOGICAL
INHIBITION OF ALDH2 ON FIRST-WINDOW NITRITE
POST-CONDITIONING. Six Caucasians were pre-treated
with disulﬁram (600 mg/day) for 2 days before the
study. In previous studies, this dose has been found
to inhibit ALDH2 fully. Nitrite was administered for
the latter 10 min of ischemia as in protocol 2.
STATISTICAL ANALYSIS. Data from each study were
analyzed by an investigator who was blinded to the
identity of the participants, their genetic status, and
the protocol used. Statistical testing was performed
using GraphPad Prism version 5.03 (GraphPad
Software, La Jolla, California). Pre-and post-
ischemia dose-response curves were compared using
repeated measures 2-way analysis of variance. Other
parametric values were compared with 2-way Student
t test and nonparametric values with Mann-Whitney
U test. A p value of <0.05 was considered statisti-
cally signiﬁcant.
RESULTS
All subjects tolerated the procedures with no com-
plications. Baseline characteristics of volunteers are
FIGURE 3 Intravenous Sodium Nitrite Induced Endothelial Post-Conditioning in
ALDH2*1/*2 Individuals, But Not ALDH2*1/*1 Individuals
(A) IR produced signiﬁcant endothelial dysfunction in ALDH2*1/*2 individuals (p <
0.0001, n ¼ 9). (B) IR produced signiﬁcant endothelial dysfunction in ALDH2*1/*1 in-
dividuals (p ¼ 0.0001, n ¼ 9). (C) Intravenous sodium nitrite (1 mg/kg/min) administered
during the ﬁnal 10 min of ischemia prevented endothelial dysfunction in ALDH2*1/*2
individuals (p¼ 0.63, n ¼ 8). (D) Intravenous sodium nitrite (1 mg/kg/min) administered
during the ﬁnal 10 min of ischemia did not prevent endothelial dysfunction in
ALDH2*1/*1 individuals (p ¼ 0.006, n ¼ 10); **p < 0.01, ***p # 0.0001. Solid circles ¼
pre-ischemia FBF-R; open circles ¼ post-ischemia FBF-R. IR ¼ ischemia–reperfusion;
other abbreviations as in Figures 1 and 2.
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17given in Table 1. All Caucasian participants were ho-
mozygous for the wild-type ALDH2 (ALDH2*1/*1)
allele. Of the East Asian participants, 11 were homo-
zygous for wild-type ALDH2 (ALDH2*1/*1) and 11 were
heterozygotes (ALDH2*1/*2). One was homozygous
for the variant ALDH2 (ALDH2*2/*2) and was
excluded from the analysis.
PROTOCOL 1: SECOND-WINDOW PRE-CONDITIONING BY
NITRITE. Twenty minutes of forearm ischemia
followed by 15 min of reperfusion caused a reduction
in FBF-R response to Ach, indicating endothelial
dysfunction in those who received placebo infusion
24 h earlier (p ¼ 0.047, n ¼ 5). One mg/kg/min sodium
nitrite administered intravenously 24 h before
IR prevented this post-ischemia endothelial dysfunc-
tion in a group of homozygous wild-type (ALDH2*1/*1)
participants (p ¼ 0.78, n ¼ 7) (Figures 2A and 2B).
PROTOCOL 2: EFFECT OF GENETIC POLYMORPHISM
ON FIRST-WINDOW NITRITE POST-CONDITIONING.
Sixteen of the 22 participants completed both studies,
but the remaining 6 chose not to participate. As a
result, 18 participants completed the placebo arm of
the study (9 ALDH2*1/*1 and 9 ALDH2*1/*2), and 18
participants completed the nitrite arm (10 ALDH2*1/*1
and 8 ALDH2*1/*2), and thus paired analysis was not
possible.
The IR protocol did not affect heart rate or blood
pressure in any group; resting heart rate and blood
pressure were similar on each study day (data not
shown). Changes in endothelium-independent FBF
were similar between groups (data not shown).
Twenty minutes of forearm ischemia induced signif-
icant endothelial dysfunction in individuals with
(p < 0.0001, n ¼ 9) or without (p ¼ 0.0001, n ¼ 9)
the ALDH2*2 allele (Figures 3A and 3B).
Plasma nitrite levels at baseline were similar in
those with and without the ALDH2*2 allele. During
studies where nitrite was administered, plasma nitrite
increased from 1.43  0.12 mmol/l to 3.39  1.23 mmol/l
in individuals with the *1 wild-type variant (p < 0.05,
n ¼ 8) but only from 1.33  0.12 mmol/l to 2.56  1.42
mmol/l in those with the *2 variant (Figure 4A). The
plasma nitrate and RXNO were not signiﬁcantly
different at baseline and were not signiﬁcantly
different at 1 min of reperfusion (data not shown).
Sodium nitrite mildly inhibited ALDH2*1 (by 6.4%; p ¼
0.04, n ¼ 3), whereas ALDH2*2 was neither stimulated
nor inhibited by nitrite (Figure 4B). The *2 variant
enzyme exhibited a rightward shift in the soluble
guanylate cyclase stimulation curve (a surrogate of NO
generation) at moderate levels of nitrite (Figure 4C).
One mg/kg/min sodium nitrite administered
intravenously during the latter 10 min of ischemiaprevented endothelial dysfunction in participants
that were heterozygous for the ALDH2*2 allele (p ¼
0.63, n ¼ 8) (Figure 3C). Homozygous wild-type in-
dividuals did not display protection (p ¼ 0.006,
n ¼ 10) (Figure 3D).
PROTOCOL 3: EFFECT OF PHARMACOLOGICAL INHIBITION
OF ALDH2 ON FIRST-WINDOW NITRITE POST-
CONDITIONING. Homozygous wild-type participants
FIGURE 4 In Vitro Studies of Plasma Nitrite and Enzyme Activity
(A) Plasma nitrite rose signiﬁcantly in normal individuals, but did not reach signiﬁcance in
those with the *2 variant (*p < 0.05, n ¼ 8 vs. 7). Solid circles ¼ ALDH2*1/*1; open
circles ¼ ALDH2*1/*2. (B) Sodium nitrite inhibited aldehyde dehydrogenase activity of
ALDH2*1 (p < 0.01 compared with baseline), but not *2, though the resting level of
activity was far lower (n ¼ 3 for each). (C) The ALDH2*2 variant enzyme exhibits a
rightward shift in the NO-generation curve in response to nitrite when compared with
the wild-type enzyme (p < 0.05, n ¼ 3). Solid line ¼ ALDH2*1; dotted line ¼ ALDH2*2.
DTT ¼ dithiothreitol; sGC ¼ soluble guanylate cyclase.
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18pre-treated with disulﬁram and administered
1 mg/kg/min sodium nitrite intravenously during the
latter 10 min of ischemia displayed signiﬁcant post-
ischemic endothelial dysfunction (p < 0.0001,
n ¼ 6), suggesting no protective effect of nitrite in this
setting (Figure 5).
DISCUSSION
We demonstrate for the ﬁrst time to our knowledge in
humans that nitrite administered 24 h before forearm
ischemia attenuates the endothelial dysfunction
following ischemia reperfusion injury. Furthermore,
we show that nitrite post-conditioning is efﬁcacious
at reducing this dysfunction in certain individuals
only, with protection depending upon ALDH2 geno-
type. In order to establish whether reduced ALDH2
activity (known to be conferred by the mutation) was
responsible for the observed effect, a group of
homozygous participants were pre-treated with
disulﬁram. Pharmacological inhibition of ALDH2
in healthy volunteers did not recapitulate the
ALDH2*1/*2 phenotype with respect to nitrite post-
conditioning.
Second-window pharmacological pre-conditioning
in humans has not been studied extensively. GTN,
exercise, and remote ischemic pre-conditioning
(RIPC) (where the stimulus for pre-conditioning is a
different organ or tissue than the one protected, most
commonly the lower limb in humans) have been
studied in humans using angioplasty and experi-
mental IR injury, but to our knowledge, our study is
novel in demonstrating a late effect of nitrite pre-
conditioning. This observation has implications for
future studies to investigate the value of nitrite pre-
conditioning in situations of predictable IR injury
such as planned cardiac surgery and organ trans-
plantation, and its additive role with ﬁrst-window
interventions.
The description of local post-conditioning has
increased interest in recruiting these protective
mechanisms in human IR syndromes where most
patients present after the onset of ischemia. Thus,
interventions timed at the phase of reperfusion may
be clinically very relevant. Human forearm model
data have suggested that pre-conditioning with ni-
trite may be effective, whereas they could not
demonstrate an effect with post-conditioning (10).
The NIAMI study in acute ST-segment elevation
myocardial infarction was also negative (11). Our re-
sults in those homozygous for wild-type ALDH2*1 are
consistent with these previous studies in demon-
strating no reduction in ischemia reperfusion injury
when nitrite is administered during ischemia.
FIGURE 5 Disulﬁram Pre-Treatment in ALDH2*1/*1
Individuals Did Not Recapitulate the Protection Seen in
ALDH2*1/*2 Individuals
Pre-treatment with disulﬁram (600 mg daily for 2 days) did
not rescue the wild-type phenotype (p < 0.0001, n ¼ 6);
***p<0.0001. Solid circles¼ pre-ischemia FBF-R; open circles¼
post-ischemia FBF-R. Abbreviations as in Figures 1 to 3.
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19Interestingly, however, our data suggest that the
post-conditioning effects of nitrite may dependent on
ALDH2 genotype. Thus, those individuals heterozy-
gous for ALDH2*2, which confers its own functional
biological effects (Figure 4), can be protected by ni-
trite at this time frame. Furthermore, simple phar-
macological inhibition of the enzyme with disulﬁram
does not confer the same phenotype as in those with
the mutation. This discrepancy in the effect of
phenotypic and pharmacological inhibition of ALDH2
is in contrast to the observation that both prevent the
protection conferred by RIPC (23), and is difﬁcult to
explain. It is possible that people with the ALDH2*2
gene change, who have abnormal enzyme function
throughout life, possess compensatory adaptations
elsewhere. Acute inhibition with disulﬁram would
not necessarily recapitulate these changes. The
resulting enzyme created in those heterozygous for
ALDH2*2 is not inert, and despite the vast number of
people possessing this gene change worldwide, study
of this enzyme has been limited. The 2 different
enzyme forms directly, and most likely also indi-
rectly, affect the metabolism and availability of ni-
trite and related species and this may well have
contributed to the result observed.
STUDY LIMITATIONS. There are several limitations to
the interpretation of this study: as with any phar-
macological study, the dose of agent used may beinappropriate. The plasma nitrite concentration ach-
ieved in wild-type individuals in the present study is
lower than that which successfully protected
myocardium in animal models of pre-conditioning
(cf. 13.8 mg/kg/min, 0.2 mmol/kg/min, aiming for a
plasma concentration of 5 to 10 mmol/l in Gonzalez et
al. [8]). However, the protective effect seen in those
with the variant enzyme, who appear to have a
smaller rise in plasma nitrite, may suggest that in the
post-conditioning phase, this dose is too high. It has
been reported that very high levels of NO may pre-
vent protection (24). Thus, it is possible that, in the
post-ischemia phase, the kinetics of nitrite meta-
bolism are altered such that this dose is not protec-
tive. However, our inability to restore protection by
pharmacological inhibition suggests that this enzyme
system alone is not responsible for these effects.
Although we cannot exclude off-target effects of
disulﬁram contributing to this observation, we
believe that the interaction between nitrite and the
ALDH2*1/*2 genotype is more nuanced than nitrite
simply augmenting the detoxifying potential of an
enzyme with reduced dehydrogenase activity (e.g.,
with respect to reactive aldehydes such as 4-hydroxy-
2-nonenal). Supporting this inference, whereas our
in vitro biochemical studies suggest that nitrite has
little effect on ALDH activity per se, the differences in
genotype nevertheless impact upon nitrite meta-
bolism. It has been proposed that nitrite triggers a
protective signaling cascade by reversible inhibition
of mitochondrial complex I, with modulation of
mitochondrial reactive oxygen species generation at
reperfusion (25); however, the relevance of this
mechanism in humans is unclear.
Because the study involves puncture of the
brachial artery, it was felt that it was not reasonable
to require more than 2 runs from each participant.
Ideally, the effect of disulﬁram and delayed protec-
tion would have been studied in the East Asian pop-
ulation, but insufﬁcient participants were recruited.
It was not possible to analyze as a crossover study,
because not all participants completed both arms of
the study. The data from placebo and nitrite runs
were analyzed separately in the same manner as
previously discussed (20,26). There was a washout
period of at least 1 week between studies that we
believe was sufﬁcient to preclude ongoing effects,
and the placebo and nitrite studies were performed in
random order. However, we cannot absolutely
exclude effects of the previous study, and hence, we
list this as a limitation. Finally, our disulﬁram group
consisted of men only, although there were no sig-
niﬁcant effects of sex found in any of the other
groups. The biochemical study of ALDH2 inhibition/
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: IR
injury is a common cause of cardiovascular injury or
death. Pre-conditioning may reduce or prevent this
injury in a variety of tissues, with effects over and
above current treatments. Results from clinical trials
thus far have been mixed, and translation to main-
stream clinical medicine has been slow, despite
increasing understanding of the relevant physiology.
Here, we show a protective effect of low-dose
systemic sodium nitrite in prevention of IR injury to
the human vascular endothelium, when administered
24 h before the insult, and additionally in some par-
ticipants (depending upon ALDH2 genotype) when
administered during ischemia.
TRANSLATIONAL OUTLOOK: Future translational
studies should examine different protocols of nitrite
dosage and timing in protection against IR injury. This
work also sheds some additional light on the central,
and complex, nature of ALDH2 in this process and
complements recent work showing a potential role of
nitrite as an innate mediator of remote ischemic pre-
conditioning.
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20activation by nitrite was investigated using the ho-
mozygous variant enzyme because it is a dominant-
negative polymorphic variant (22).
Clinical translation in the area of pre-conditioning
and post-conditioning, despite ongoing efforts, has
been slow. Direct activation of the ALDH2 pathway
remains an attractive area of investigation (27);
however, the negative NIAMI study (11) has some-
what reduced enthusiasm for further trials of exog-
enous nitrite in ischemia. More recent work has
focused on a potential role of endogenous nitrite in
cytoprotection, for example as a mediator of remote
ischemic pre-conditioning (28). In a mouse model of
myocardial infarction, this study conﬁrmed the role
of nitrite by use of a nitrite scavenger to abolish the
effect of RIPC, and then recapitulated this protection
with nitrite-supplemented plasma. In their editorial
accompanying this study, Corti and Gladwin (29)
argued that reliance on animal models may be
limiting our ability to translate this undoubtedly
exciting physiological process to mainstream medi-
cine. Equally, human ischemic models (such as the
one used here) may not translate to other tissues or
organs, or to pathological states, though they may
well provide insight into the mechanisms involved.
It is generally agreed that cytoprotection proceeds
down a ﬁnal common pathway (30), so it seems
likely that protection by nitrite seen in the forearm
may be achieved in other tissues under the correct
conditions. However, as Corti and Gladwin (29)
argue, multiple factors—the nitrite dose, the plasma
levels achieved, and the timing of intervention—
create a complex system and are all critical to the
successful translation of cytoprotection to human
patients.
CONCLUSIONS
This proof-of-concept study of endothelial protection
in healthy volunteers provides evidence that inorganicnitritemay have therapeutic use to prevent IR injury in
man. Speciﬁcally, we demonstrate nitrite-induced
second-window pre-conditioning in humans and
identify the important impact of a common global
polymorphism on post-conditioning with nitrite.
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